Clinical utility of novel biomarkers for cardiovascular disease risk stratification
详细信息 查看全文
- 作者：Maurizio Averna (1)
Davide Noto (2) - 关键词：Predictive power ; Cardiovascular risk ; Biomarkers ; Atherosclerosis
- 刊名：Internal and Emergency Medicine
- 出版年：2012
- 出版时间：October 2012
- 年：2012
- 卷：7
- 期：3-supp
- 页码：263-270
- 全文大小：183KB
- 参考文献：1. Wilson PW, D’Agostino RB, Levy D et al (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837-847 CrossRef
2. Conroy RM, Pyorala K, Fitzgerald AP et al (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24:987-003 CrossRef
3. Hippisley-Cox J, Coupland C, Vinogradova Y et al (2007) Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 335:136 CrossRef
4. Helfand M, Buckley DI, Freeman M, Fu R, Rogers K, Fleming C, Humphrey LL (2009) Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann Intern Med 151:496-07
5. Atkinson AJ, Colburn WA, DeGruttola VG, DeMets DL, Downing GJ, Hoth DF, Oates JA, Peck CC, Schooley RT, Spilker RA, Woodcock J, Zeger SL (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89-5 CrossRef
6. Biasillo G, Leo M, Della Bona R, Biasucci LM (2010) Inflammatory biomarkers and coronary heart disease: from bench to bedside and back. Intern Emerg Med 5(3):225-33 CrossRef
7. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH (1998) Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98(8):731-33 CrossRef
8. Boekholdt SM, Hack CE, Sandhu MS, Luben R, Bingham SA, Wareham NJ, Peters RJ, Jukema JW, Day NE, Kastelein JJ, Khaw KT (2006) C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-003. Atherosclerosis 187(2):415-22 CrossRef
9. Folsom AR, Aleksic N, Catellier D, Juneja HS, Wu KK (2002) C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 144(2):233-38 CrossRef
10. Bisoendial RJ, Kastelein JJ, Stroes ES (2007) C-reactive protein and atherogenesis: from fatty streak to clinical event. Atherosclerosis 195(2):e10–e18 CrossRef
11. Lagrand WK, Niessen HW, Wolbink GJ et al (1997) C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 95(1):97-03 CrossRef
12. Torzewski M, Torzewski DE, Bowyer et al (1998) C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 18(9):1386-392 CrossRef
13. Chang MK, Binder CJ, Torzewski M, Witztum JL (2002) C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA 99(20):13043-3048 CrossRef
14. Burke AP, Tracy RP, Kolodgie F et al (2002) Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation 105(17):2019-023 CrossRef
15. Mora S, Ridker PM (2006) Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)–can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol 97(2A):33A-1A CrossRef
16. Norata GD, Garlanda C, Catapano AL (2010) The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. Trends Cardiovasc Med 20(2):35-0 CrossRef
17. Sprague AH, Khalil RA (2009) Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol 78(6):539-52 CrossRef
18. Aukrust P, Halvorsen B, Yndestad A, Ueland T, ?ie E, Otterdal K, Gullestad L, Dam?s JK (2008) Chemokines and cardiovascular risk. Arterioscler Thromb Vasc Biol 28(11):1909-919 CrossRef
19. Hung MJ, Cheng WJ, Cheng CW, Li LF (2006) Comparison of serum levels of inflammatory markers in patients with coronary vasospasm without significant fixed coronary artery disease versus patients with stable angina pectoris and acute coronary syndromes with significant fixed coronary artery disease. Am J Cardiol 97(10):1429-434 CrossRef
20. Hojo Y, Ikeda U, Takahashi M, Shimada K (2002) Increased levels of monocyte-related cytokines in patients with unstable angina. Atherosclerosis 161(2):403-08 CrossRef
21. Cusack MR, Marber MS, Lambiase PD, Bucknall CA, Redwood SR (2002) Systemic inflammation in unstable angina is the result of myocardial necrosis. J Am Coll Cardiol 39(12):1917-923 CrossRef
22. Noto D, Cottone S, Baldassare Cefalù A, Vadalà A, Barbagallo CM, Rizzo M, Pernice V, Minà M, Fayer F, Cerasola G, Notarbartolo A, Rocco Averna M (2007) Interleukin 6 plasma levels predict with high sensitivity and specificity coronary stenosis detected by coronary angiography. Thromb Haemost 98(6):1362-367
23. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ (1996) Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 271:736-41 CrossRef
24. Wassmann S, Stumpf M, Strehlow K, Schmid A, Schieffer B, Bo¨hm M (2004) Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res 94(4):534-41 CrossRef
25. Yanes LL, Romero DG, Cucchiarelli VE, Fortepiani LA, Gomez-Sanchez CE, Santacruz F (2005) Role of endothelin in mediating postmenopausal hypertension in a rat model. Am J Physiol Regul Integr Comp Physiol 288(1):R229–R233 CrossRef
26. Anand SX, Viles-Gonzalez JF, Badimon JJ, Cavusoglu E, Marmur JD (2003) Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb Haemost 90:377-84
27. Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C (2009) The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 54(8):669-77 CrossRef
28. de Lemos JA, Morrow DA, Blazing MA, Jarolim P, Wiviott SD, Sabatine MS, Califf RM, Braunwald E (2007) Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. J Am Coll Cardiol 50(22):2117-124 CrossRef
29. Mulvihill N, Foley J, Murphy R, Crean P, Walsh M (2000) Evidence of prolonged inflammation in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol 36:1210-216 CrossRef
30. Blankenberg S, Rupprecht H, Bickel C, Peetz D, Hafner G, Tiret L, Meyer J (2001) Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 104:1336-342 CrossRef
31. Rallidis L, Gika H, Zolindaki M, Xydas TA, Paravolidakis KE, Velissaridou AH (2003) Usefulness of elevated levels of soluble vascular cell adhesion molecule-1 in predicting in-hospital prognosis in patients with unstable angina pectoris. Am J Cardiol 92:1195-197 CrossRef
32. Lin L, Park S, Lakatta EG (2009) RAGE signaling in inflammation and arterial aging. Front Biosci 1(14):1403-413 CrossRef
33. Choi KM, Yoo HJ, Kim HY, Lee KW, Seo JA, Kim SG, Kim NH, Choi DS, Baik SH (2009) Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness. Int J Cardiol 132(1):96-01 CrossRef
34. Geroldi D, Falcone C, Minoretti P, Emanuele E, Arra M, D’Angelo A (2006) High levels of soluble receptor for advanced glycation end products may be a marker of extreme longevity in humans. J Am Geriatr Soc 54:1149-150 CrossRef
35. Palazzuoli A, Antonelli G, Quatrini I, Nuti R (2011) Natriuretic peptides in heart failure: where we are, where we are going. Int Emerg Med 6(1):63-8 CrossRef
36. Nishikimi T, Kuwahara K, Nakao K (2011) Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides. J Cardiol 57(2):131-40 CrossRef
37. Doi Y, Ninomiya T, Hata J, Hata J, Hirakawa Y, Mukai N, Mukai N, Mukai N, Ikeda F, Fukuhara M, Iwase M, Kiyohara Y, Kiyohara Y (2011) N-terminal pro-brain natriuretic peptide and risk of cardiovascular events in a Japanese community: the Hisayama Study. Arterioscler Thromb Vasc Biol 31(12):2997-003 CrossRef
38. Rodseth RN, Lurati Buse GA, Bolliger D, Burkhart CS, Cuthbertson BH, Gibson SC, Mahla E, Leibowitz DW, Biccard BM (2011) The predictive ability of pre-operative B-type natriuretic peptide in vascular patients for major adverse cardiac events: an individual patient data meta-analysis. J Am Coll Cardiol 58(5):522-29 CrossRef
39. Gaede P, Hildebrandt P, Hess G, Parving HH, Pedersen O (2005) Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia 48(1):156-63 CrossRef
40. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D’Agostino RB, Vasan RS (2006) Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 355(25):2631-639 CrossRef
41. Cushman M, Arnold AM, Psaty BM et al (2005) C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the Cardiovascular Health Study. Circulation 112:25-1 CrossRef
42. Lloyd-Jones DM, Nam BH, D’Agostino RB, Levy D, Murabito JM, Wang TJ et al (2004) Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults. JAMA 291:2204-211 CrossRef
43. Hinds DA, Stuve LL, Nilsen GB, Halperin E, Eskin E, Ballinger DG et al (2005) Whole-genome patterns of common DNA variation in three human populations. Science 307:1072-079 CrossRef
44. McPherson R, Pertsemlidis A, Kavaslar N, Stewart AFR, Roberts R, Cox DR et al (2007) A common allele on chromosome 9 associated with coronary heart disease. Science 316:1488-491 CrossRef
45. Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, Jonasdottir A et al (2007) A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 316:1491-493 CrossRef
46. Palomaki GE, Melillo S, Bradley LA (2010) Association between 9p21 genomic markers and heart disease: a meta-analysis. JAMA 303:648-56 CrossRef
47. Assimes TL, Knowles JW, Basu A, Iribarren C, Southwick A, Tang H et al (2008) Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multi-ethnic ADVANCE study. Hum Mol Genet 17:2320-328 CrossRef
48. Chen Z, Qian Q, Ma G, Wang J, Zhang X, Feng Y et al (2009) A common variant on chromosome 9p21 affects the risk of early-onset coronary artery disease. Mol Biol Rep 36:889-93 CrossRef
49. Assimes TL, Knowles JW, Basu A, Iribarren C, Southwick A, Tang H et al (2008) Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multi-ethnic ADVANCE study. Hum Mol Genet 17:2320-328 CrossRef
50. Pasmant E, Laurendeau I, He-ron D, Vidaud M, Vidaud D, Bie` che I (2007) Characterization of a germline deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. Cancer Res 67:3963-969 CrossRef
51. Patel RS, Su S, Neeland IJ, Ahuja A, Veledar E, Zhao J et al (2010) The chromosome 9p21 risk locus is associated with angiographic severity and progression of coronary artery disease. Eur Heart J 31:3017-023 CrossRef
52. Ardissino D, Berzuini C, Merlini PA, Mannucci MP, Surti A, Burtt N et al (2011) Influence of 9p21.3 genetic variants on clinical and angiographic outcomes in early-onset myocardial infarction. J Am Coll Cardiol 58:426-34 CrossRef
53. Anderson JL, Horne BD, Kolek MJ, Muhlestein JB, Mower CP, Park JJ et al (2008) Genetic variation at the 9p21 locus predicts angiographic coronary artery disease prevalence but not extent and has clinical utility. Am Heart J 156:1155-162 CrossRef
54. Dandona S, Stewart AFR, Roberts R (2010) Genomics in coronary artery disease: past, present and future. Can J Cardiol 26(Suppl A):56A-9A CrossRef
55. Preuss M, K?nig IR, Thompson JR, Erdmann J, Absher D, Assimes TL et al and on behalf of the CARDIoGRAM Consortium. Design of the coronary ARtery disease genome-wide replication and meta-analysis (CARDIoGRAM) study: a genome-wide association meta-analysis involving more than 22,000 cases and 60,000 controls. Circ Cardiovasc Genet. 2010;3:475-83
56. Schunkert H, K?nig IR, Kathiresan S, Reilly MP, Assimes TL, Holm H et al (2011) Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet 43:333-38 CrossRef
57. Reilly MP, Li M, He J, Ferguson JF, Stylianou IM, Mehta NN et al (2011) Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet 377:383-92 CrossRef
58. Paynter NP, Chasman DI, Pare-G, Buring J, Cook NR, Miletich JP, Ridker PM (2010) Association between a literature-based genetic risk score and cardiovascular events in women. JAMA 303:631-37 CrossRef
59. Davies RW, Dandona S, Stewart AFR, Chen L, Ellis S, Tang WH et al (2010) Improved prediction of cardiovascular disease based on a panel of single nucleotide polymorphisms identified through genome-wide association studies. Circ Cardiovasc Genet 3:468-74 CrossRef
60. Talmud PJ, Cooper JA, Palmen J, Lovering R, Drenos F, Hingorani AD, Humphries SE (2008) Chromosome 9p21.3 coronary heart disease locus genotype and prospective risk of CHD in healthy middle-aged men. Clin Chem 54:467-74 CrossRef
61. Roberts R, Stewart A (2012) 9p21 and the genetic revolution for coronary artery disease. Clin Chem 58:104-12 CrossRef - 作者单位：Maurizio Averna (1)
Davide Noto (2)
1. Department of Internal Medicine and Medical Specialties-DIMIS, University of Palermo, Palermo, Italy
2. Department of Emerging Diseases, University Hospital (AOUP) “Paolo Giaccone- University of Palermo, Palermo, Italy
文摘
Over the past few decades, a number of coronary artery disease (CAD) and cardiovascular disease (CVD) risk factors have been identified. The predictive power of “conventional-risk factors have been validated by observational, prospective and intervention studies. Nevertheless, all attempts to exactly predict the individual risk for CAD have failed, biased by a large number of incorrectly risk-classified subjects. To improve cardiovascular (CV) risk prediction, a large number of genetic and/or non-genetic biomarkers have been discovered and tested against the “classical-risk factors for their power to predict CV risk. Only few of them had a significant improvement over the predictive models. In this paper, the most investigated biomarkers will be discussed and the evidence of their use as predictors of CV will be questioned.